Stocks of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) traded higher last session on Wall Street, down -5.36% to $1.06.
According to the data, Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) has 2 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $4.00, we find $6.00. Given the previous closing price of $1.12, this indicates a potential upside of 435.71 percent. CDIO stock price is now 145.89% away from the 50-day moving average and -34.33% away from the 200-day moving average. The market capitalization of the company currently stands at $8.61M.
A total of 0 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
In other news, Dogan Timur, Chief Technology Officer bought 16,481 shares of the company’s stock on Aug 31. The stock was bought for $8,982 at an average price of $0.55. Upon completion of the transaction, the Chief Technology Officer now directly owns 128,345 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 31, Chief Executive Officer Dogan Meeshanthini bought 16,481 shares of the business’s stock. A total of $8,982 was incurred on buying the stock at an average price of $0.55. This leaves the insider owning 128,345 shares of the company worth $0.14 million. A total of 32.36% of the company’s stock is owned by insiders.
During the past 12 months, Cardio Diagnostics Holdings Inc has had a low of $0.17 and a high of $8.50. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 1.23, and a quick ratio of 1.23. The fifty day moving average price for CDIO is $0.4312 and a two-hundred day moving average price translates $1.6140 for the stock.
The latest earnings results from Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.39, missing analysts’ expectations of -$0.18 by -0.21. This compares to -$0.17 EPS in the same period last year. The net profit margin was -94732.84% and return on equity was -33.02% for CDIO. For the current quarter, analysts expect CDIO to generate $120k in revenue.
Cardio Diagnostics Holdings Inc(CDIO) Company Profile
Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.